Current Trends In Identifying And Treating Newborns With Withdrawal Syndromes 6/24/2010.

Slides:



Advertisements
Similar presentations
Neonatal Abstinence Syndrome: Taking Care of Mom and Baby Heather Rodman, PharmD PGY-2 Pediatric Pharmacy Resident Peyton Manning Children’s Hospital St.
Advertisements

Dosing and patient management requirements during induction, stabilization, and detoxification with buprenorphine Matthew A. Torrington MD Clinical Research.
Neonatal Abstinence Syndrome: A Family Centered Approach to Care Kelly Outlaw, M.S., CCLS.
Moms on Meds Substance Abuse During Pregnancy: Jennifer Anderson Maddron, M.D.
Pharmacological Treatment of Opioid Dependence during Pregnancy: Methadone and Buprenorphine Overview Karol Kaltenbach, PhD Maternal Addiction Treatment.
Putting the Pieces Together Perspectives from an Opioid Addiction Treatment Program.
Neonatal Abstinence Syndrome. Risks for developing NAS Opioids – Opiate derivatives, interact with mu-opioid receptor Abstinence syndrome (withdrawal)
SUBSTANCE ABUSE The Drug-Exposed Infant
“Association of OPRM1 and COMT Single Nucleotide Polymorphisms with Hospital Length of Hospital Stay and Treatment of Neonatal Abstinence Syndrome” E Wachman,
V.Sideri, C.Vliora, A.Daskalaki, P.Mexi-Bourna, K.Kleanthous, M.Soulioti, G. Kyrkou, N.Bournas, V.Papaevangelou 3 rd Pediatric Clinic of the University.
Childhood Development Affected by Prenatal Drug Abuse Milene Francis Psychology 1100 April, 2014.
Overview of Substance Exposed Newborns Data and Trend Overview.
Education Guide for Parents and Caregivers. Neonatal Abstinence Syndrome (NAS) NAS may present in a baby who is exposed to medication taken by the mother.
Chapter 13 Opioids.
Injectable Opioid Treatment in England Clinical Experience Rob van der Waal.
John R. Kasich, Governor Tracy J. Plouck, Director Andrea Boxill, Deputy Director Andrea Boxill, Deputy Director Governor’s Cabinet Opiate Action Team.
Lisa Hackenmueller Caitlin McNamara Katrina Awker.
1 Neonatal Adverse Events Associated with in utero SSRI/SNRI Exposure Robert Levin, M.D. Medical Reviewer DNDP FDA.
A healthy neonate was born to a GBS + mother that was given Amp only 3 hours prior to delivery. Since you know that was not effective treatment, you decide.
Pediatric AC 6/9/041 Neonatal withdrawal syndrome with Serotonin Reuptake Inhibitors Office of Drug Safety Review Kathleen Phelan, R.Ph., Safety Evaluator.
1 Lotronex ® (alosetron HCl) Tablets Risk-Benefit Issues Victor F. C. Raczkowski, M.D. Director, Division of Gastrointestinal and Coagulation Drug Products.
MATERNAL & NEONATAL WITHDRAWAL SYNDROME BY: Dr. F.Goudarzi Clinical Toxicologist SUMS.
Neonatal Abstinence Syndrome
Methamphetamine (MA) use continues to be a significant problem in the United States. The number of adults age 12 and over who have tried MA once in their.
Malformation of Extremities Malformation of Extremities.
Neonatal Abstinence Syndrome Lauritz Meyer, MD September 11, 2015 SDPA Conference.
Initial Neonatal Work-up First urine-will only detect very recent substance use First meconium-will detect substances used after 20 weeks gestation StandardizedNAS.
Effect of Depression on Smoking Cessation Outcomes Sonne SC 1, Nunes EV 2, Jiang H 2, Gan W 2, Tyson C 1, Reid MS 3 1 Medical University of South Carolina,
Substance Use & Abuse in Pregnancy Janet L. Mitchell, M.D., M.P.H., F.A.C.O.G. Consultant on Women’s Health Addiction Research & Treatment Corporation.
1 TOPIC 10 SUBSTANCE RELATED DISORDER. Classification of Substance-Related Disorders  Substance Abuse and Dependence  Substance abuse involve a pattern.
INFANT BIRTH OUTCOMES AMONG SUBSTANCE USING WOMEN: WHY QUITTING SMOKING IS JUST AS IMPORTANT AS QUITTING HARDER DRUGS Beth Bailey, PhD; Judy McCook, PhD,
Drug Treatment Issues in Drug-Dependent, Pregnant Women Hendrée E. Jones, Ph.D. Department of Psychiatry and Behavioral Sciences Johns Hopkins University.
Pregnancy and Drug Abuse Eva Janecek-Rucker. Learning Objectives 1.To develop a knowledge base of the effects of substances of abuse (e.g., alcohol, cocaine,
Pain Management Laura Bergs FNP. Definition of Chronic Pain Anyone with pain greater than 3 months Anyone with pain greater than 3 months Pain An unpleasant.
Module IV: Identification of Patients for Buprenorphine Treatment BUPRENORPHINE TREATMENT: A Training For Multidisciplinary Addiction Professionals.
Stimulants: An Overview Nature of Stimulants Most widely consumed drug in the United States Such drugs increase alertness and increase energy Examples.
Treating Pregnant Opioid Dependent Women: Examining Buprenorphine and Methadone Hendrée E. Jones, Ph.D. Associate Professor Department of Psychiatry and.
Improving Care for Opioid Exposed Newborns September 11, 2006 NNEPQIN Dartmouth Hitchcock Medical Center Anne Johnston, MD Associate Professor of Pediatrics.
Table 1. Prediction model for maximum daily dose of buprenorphine-naloxone in a 12-week treatment condition Baseline Predictors Maximum Daily Dose Standardized.
Treatment of Opioid Dependency in Pregnancy and Strategies to Reduce Neonatal Abstinence Syndrome.
Substance abuse. Substance abuse, dependence, withdrawal, tolerance, and demographics Substance abuse, dependence, withdrawal, tolerance, and demographics.
Patty Zetterberg, MSN, C-PNP Director, Clinical Operations Medical Practice Management East Tennessee Children’s Hospital Neonatal Abstinence Syndrome.
By: Nicole Stevens  A syndrome of drug withdrawal with non- specific signs and symptoms that may occur in babies following in-utero drug exposure. 
Elizabeth E. Krans, MD, MSc Assistant Professor, University of Pittsburgh Magee-Womens Research Institute Department of Obstetrics, Gynecology and Reproductive.
Neonatal Abstinence Syndrome
TM Substance Use Transitions from Initial Use to Regular Use to Discontinuance Ralph S. Caraballo, Ph.D., MPH Office on Smoking and Health, CDC, Atlanta.
The Problem of Neonatal Abstinence Syndrome (NAS) Opiates and Pregnancy.
Buprenorphine {Suboxone®, Subutex®}
Anne Merewood PhD MPH IBCLC Associate Professor of Pediatrics, Boston University School of Medicine Consultant to the Rocky Mountain Tribal Leaders Council.
Abusing Drugs During Pregnancy is Child Abuse Hannah Magyar CP English 12 Mrs. Mahoney May 5, 2015.
Neonatal Abstinence Syndrome: Preserving the Infant-Maternal Bond Haneme Idrizi, MD, FAAP Assistant Professor of Pediatrics, University of Texas Health.
Neonatal Abstinence Syndrome
Specific issues in drug use and pregnancy. Pregnant women who use drugs (RCOG, 2010) One of the challenges for pregnant women who use drugs is that they.
Antenatal Case Study Serah Mungai & Hywel Mackey.
Care of the Neonate with Prenatal Opioid Exposure – Advanced Practice
Medication Assisted Treatment and Pregnancy
Substance Abuse During Pregnancy: The Littlest Victims
Screening and Referral
Neonatal Abstinence Syndrome: An emerging issue for Part C systems?
Alcohol, Other Drugs, and Health: Current Evidence
Developmental Outcomes in Infants of Opiate Addicted Women: Effects on Cognitive and Motor Development B.A. Logan, N.A. Heller, D.G. Morrison, H. Shrestha,
Medication Assisted Treatment and Pregnancy
Neonatal Abstinence Syndrome
Neonatal Abstinence Syndrome
WisPQC Standardized Protocol Webinar for NAS/NOWS Initiative
BoRN ADDICTED: Neonatal Abstinence syndrome
Jonathan Davis, MD Chief of Newborn Medicine
ADDICTION
NEONATAL ABSTINENCE SYNDROME
Dr. Sarah Fernandez PGY4 NOSM, Pediatrics, Thunder Bay Campus
Presentation transcript:

Current Trends In Identifying And Treating Newborns With Withdrawal Syndromes 6/24/2010

Substance Exposed Newborns Barbituates Selective Serotonin Re-uptake inhibitors Opiates Marijuana Anti-psychotics Benzodiazepines Alcohol Tobacco Caffeine Amphetamines Cocaine

Substance Exposed Newborns Drug Use in Pregnant Women 2003 National Survey On Drug Use And Health. 4.3% of pregnant women, age years, reported using illicit drugs. Approximately 170,000. Drug use during pregnancy typically decreases as pregnancy progresses.

Opiates US 1999 National Household Survey on Drug Abuse reported that 6.7% of people reported illicit drug use in the last month. 0.1% heroin use. 3.4% of pregnant women reported illicit drug abuse. Approximately 3,000 pregnant women use opiates during there pregnancy each year in the United States.

Opiates Withdrawal signs in exposed infants are variable and not all exposed infants experience withdrawal % of infants will experience withdrawal No resolution to the questions surrounding maternal opiate dose and withdrawal frequency or severity. Literature split evenly on either side of this issue.

Opiates Scoring Systems Neonatal Abstinence Scoring System Finnegan Lipsitz Tool Neonatal Withdrawal Inventory Ostrea

Neonatal Abstinence Scoring System

Opiates Neonatal Abstinence Scoring System Neuromotor Tremors, hyperreflexia, inconsolable cry. Metabolic/Respiratory Hyperthermia, mottling, tachypnea. Gastrointestinal Frequent stooling, diarrhea, poor PO feeding, emesis. Score is totaled for each time point.(Feeding) 3 successive scores totaling 24 or more require treatment.

Opiates Treatment Options Neonatal Morphine Solution Methadone Phenobarbital Clonidine Partial Agonists/Antagonists

Opiates Infant with 3 scores totaling 24 or more. Neonatal Morphine Solution starts at 0.4 mg/kg/day. Every 3-4 hours depending on feeding schedule. Infant continues to be assessed with each dose. Up-titration continues as infant continues to have elevated scores.

Opiates Infant stabilized on same dose for 48 hours. Infant is initially weaned every 48 hours based upon continued clinical stability without signs of NAS. Cessation variable depending upon institution, 0.15 mg/kg/day. Observation off medication for 48 hours.

Opiates Phenobarbital First or second line agent. Loading dose 20mg/kg/day or 10 mg/kg/day. Starting or maintenance dose. 3-5 mg/kg/day.

Opiates Clonidine Adjunctive therapy at this point in time. Oral or transdermal patch delivery system. Recent randomized controlled trial demonstrated that oral clonidine as an adjunct to diluted tincture of opium reduced length of therapy.

Opiates Preterm Infants Infants born preterm seem to demonstrate fewer withdrawal signs then full term infants. Infants born preterm that do require treatment for neonatal abstinence ultimately require lower doses of neonatal opium solution and shorter courses of therapy.

Benzodiazepines Signs of neonatal withdrawal mimic the signs of withdrawal from opiates. Poorly described and few populations of infants have been investigate only exposed to benzodiazepines. No treatment for abstinence from benzodiazepines has been studied as mono-therapy.

Benzodiazepines Frequently complicates opiate addiction in pregnant women. Infants with concomitant opiate and benzodiazepine exposure often experience a more complicated withdrawal course. No quantification of this impact has yet been published.

Cocaine Cocaine exposure likely leads to a toxicity and not a withdrawal syndrome. Infants often demonstrate many of the signs of opiate withdrawal. Hyper-irritability, tachycardia, inconsolable cry. Often present though early after delivery. No specific therapy for cocaine exposure.

Selective Serotonin Re-uptake INhibitors Widely used and studied in pregnant women. Reports of an abstinence syndrome in infants still in small numbers in comparison to the large numbers of exposed women. Several reports describe a withdrawal syndrome similar to opiates. May more likely represent a toxicity and not true withdrawal syndrome.